CLX

RH (RH) stock surged 9.5% to $140.15 on strong volume, driven by expansion of its RH Estates collection, new gallery openings, and international expansion plans. However, the company's consensus EPS estimate for the upcoming quarter was revised 30.6% lower over the past 30 days, with earnings expected to decline 60.8% year-over-year.

The stock carries a Zacks Rank #3 (Hold) rating. Clorox (CLX) also gained 4.6% to $88.66, with a modest EPS estimate revision of -1.2% and a Zacks Rank #4 (Sell) rating.

Consumer staples companies PepsiCo, McCormick, Hormel, and Clorox are trading near 52-week lows due to headwinds including changing consumer preferences toward healthier products, budget constraints, and rising costs. However, these companies offer attractive dividend yields (4.1%-5.7%) and have proven track records as dividend growers, making them potentially opportunistic buys for long-term dividend investors.

Procter & Gamble is prioritizing product innovation, AI integration, and brand superiority to accelerate organic sales growth. Key successes include double-digit Baby Care growth in China and Tide's return to growth. Competitors Church & Dwight, Colgate-Palmolive, and Clorox are similarly investing in innovation pipelines and premiumization strategies to strengthen market positions, though PG faces challenges with modest 1% organic sales growth in FY26.

Five consumer goods stocks trading near 52-week lows offer attractive dividend yields (3.6%-7.6%) despite market headwinds from tariffs and shifting consumer behavior. PepsiCo and Hershey present turnaround opportunities, while General Mills appeals to patient income investors. Clorox and Kraft Heinz carry sustainability risks due to cash flow concerns and debt levels.

Clorox offers an attractive 6% dividend yield with a record date of Oct. 28 for its $1.25 quarterly payout. Investors would need 1,000 shares (approximately $83,440) to generate $5,000 in annual dividends. While the company has raised dividends for 49 consecutive years and is approaching Dividend King status, concerns exist regarding its unsustainable payout ratio exceeding 103% and weak stock performance over the past five years.

In a comparison of two major consumer staples companies, Colgate-Palmolive emerges as the stronger investment choice due to its global diversification, consistent growth profile, and strong emerging-market performance. While Clorox offers a cheaper valuation and transformation potential through its GOJO acquisition and ERP improvements, it faces headwinds from elevated inflation, muted demand, and the need to rebuild organic sales momentum.

The article recommends three consumer staples stocks as long-term holdings: PepsiCo, which is pivoting toward healthier products with improving financials and a low P/E ratio; J.M. Smucker, benefiting from strong coffee brands and rising profitability; and Clorox, a distressed company offering an attractive 6.1% dividend yield despite current challenges. All three stocks feature strong brand portfolios and consistent dividend growth histories.

Clorox has faced significant difficulties since the economic reopening following the pandemic boom. The company, which experienced strong business during COVID-19, has struggled with multiple challenges in recent years as consumer behavior and market conditions have normalized.

The Clorox Company is executing a strategic transformation focused on rebuilding market share and enhancing growth through the GOJO Industries acquisition, which significantly expands its health and hygiene portfolio to over half of net sales. The company has completed its five-year digital transformation program and expects productivity benefits from fiscal 2027 onwards. Clorox is increasing innovation spending in health, wellness, and pet care categories while improving brand relevance through targeted promotions and packaging improvements.

The Clorox Company (CLX) is experiencing elevated implied volatility in its October 2026 put options, signaling market expectations for significant price movement. However, the fundamental outlook remains weak, with Clorox holding a Zacks Rank #3 (Hold) rating and six analysts downgrading estimates over the past 60 days, reducing consensus earnings estimates from $1.26 to $0.99 per share.

Colgate-Palmolive is strengthening its market position through innovation, premiumization of oral-care products, and expansion in emerging markets. The company is introducing differentiated products targeting whitening, sensitivity, and gum health, while leveraging its strong global brands.

However, sustaining momentum depends on balancing pricing with volume, successful product launches, and cost management. Colgate trades at a premium valuation (21.5X forward P/E vs. industry 18.4X) with modest EPS growth projected at 4.9% for 2026 and 5.2% for 2027.